For the roughly 100,000 men diagnosed annually with intermediate-risk prostate cancer in the U.S., treatment choice increasingly hinges not just on survival odds but on preserving everyday function. A head-to-head comparison of two radiation strategies now offers the most rigorous data yet on whether the faster, fewer-session approach truly holds up against the established standard—and the answer carries real implications for treatment scheduling, cost, and patient burden.
This JAMA-published Phase III randomized controlled trial directly compared stereotactic body radiotherapy (SBRT)—which delivers ablative radiation doses across just four to five sessions—against moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT), typically administered over roughly 20–28 fractions. The trial's primary endpoints were urinary and bowel quality-of-life outcomes alongside disease-free survival in patients with localized intermediate-risk prostate cancer. Superiority of SBRT was the hypothesis under test, meaning researchers sought evidence that the ultra-abbreviated regimen would outperform—not merely match—the comparator on both functional and oncologic grounds.
This study lands at a pivotal moment in prostate radiotherapy. SBRT's appeal has grown steadily since PACE-B and earlier single-arm data suggested comparable biochemical control with far fewer clinic visits. However, superiority—a more demanding statistical bar than non-inferiority—has not previously been demonstrated in a large randomized setting. The JAMA publication signals the field is ready for definitive guidance. A key limitation worth noting is that intermediate-risk prostate cancer is itself heterogeneous; favorable and unfavorable intermediate-risk subgroups may respond differently, and longer follow-up remains essential for detecting late genitourinary or rectal toxicity that can emerge years post-treatment. If SBRT does not achieve superiority but demonstrates equivalence, the practical upside—fewer treatment days, lower patient travel burden, potential cost reduction—still makes it clinically meaningful. This trial's findings are likely to influence guideline updates from ASTRO and EAU in the near term.